SITRYX THERAPEUTICS LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -87.1%

  £23,312,793 → £3,011,297

• Cash

  -48%

  £29,506,210 → £15,334,663

• Net assets

  -32.4%

  £28,136,205 → £19,029,355

• Employees

  +6.5%

  46 → 49

• Operating profit

  -1,195.8%

  £2,278,125 → -£24,963,959

• Profit before tax

  -742.6%

  £3,765,446 → -£24,196,945

• Wages

  +11.2%

  £5,194,198 → £5,774,063

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

RSM UK Audit LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors have prepared forecasts based on known available funds, including scenario analysis considering the ability to extend the use of those funds. Based on these forecasts, which include known post year end receipts totalling £6.9m from convertible loan notes issued in February 2026, the directors are confident that, as at the time of approving the financial statements, the group and company has adequate resources to continue in operational existence for the foreseeable future as a minimum for a period of at least 12 months from the date of approval of these financial statements. Thus the directors have adopted the going concern basis of accounting in preparing the financial statements.”

Group structure

1. SITRYX THERAPEUTICS LIMITED · parent
   1. Sitryx Therapeutics Inc 100% · United States of America · Research & Development

Significant events

• “The Group completed a Phase 1a clinical trial of potential disease modifying treatment for atopic dermatitis with SYX-5219, a novel, oral and targeted pyruvate kinase M2 activator which modulates B and T lymphocyte activity at the specific sites of skin inflammation.”
• “approval was granted for the Phase 1b clinical trial in patients by the FDA, MHRA and the EMA.”
• “The Group nominated SIT-047 a candidate as a novel, oral MTHFD2 inhibitor for clinical development in psoriatic arthritis.”
• “The Group also regained rights to SYX-1042, an itaconate mimetic for chronic autoimmune and inflammatory diseases, from Eli Lilly.”
• “The Group reached various performance milestones during the year, which triggered milestone receipts into capital from the Series A extension undertaken in 2023.”
• “The company issued convertible loan notes to existing investors in February 2026 totalling £6.9m.”
• “A cumulative fixed rate dividend arises in all Preferred shares at the subscription price from the date on which each share was first issued at a rate of 8% per annum. As there are no distributable reserves, this has not been provided for but the right to the dividend has been recognised as a contingent liability. The cumulative fixed rate dividend as at the reporting date for all of the Preferred Shares in issue is £20,342,364 (2024: £15,503,995).”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

9

last 12 months

Capital events

4

last 24 months

Officers appointed

1

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.